The Food and Drug Administration Oct. 15 removed epinephrine from the lists of drugs authorized for temporary compounding during the COVID-19 public health emergency by outsourcing facilities and state-licensed pharmacies or federal facilities not registered as outsourcing facilities.

FDA said epinephrine’s removal is based on increased supplies of FDA-approved epinephrine products used to treat hospitalized COVID-19 patients.

Related News Articles

Headline
The Department of Health and Human Services yesterday released initial data on how states and territories plan to use their share of 100 million rapid point-of…
Headline
According to an analysis of COVID-19 hospitalization data from 13 states, released today by the Centers for Disease Control and Prevention, 6% of adults…
Headline
The Food and Drug Administration yesterday approved Veklury (remdesivir) to treat COVID-19 patients age 12 and older who are hospitalized and weigh…
Headline
To continue amplifying the important message of protecting against both the flu and COVID-19, AHA’s United Against the Flu campaign today released new…
Perspective
A COVID-19 vaccine is likely coming soon. Whether it’s next month, at the end of the year or in early 2021, many scientific experts believe we will have one or…
Headline
Three leadership capabilities consistently rise to the top when Andy Shin, chief operating officer for the AHA’s Center for Health Innovation, interviews…